{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:27:48Z","timestamp":1780824468269,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T00:00:00Z","timestamp":1467936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This report describes initiation of apheresis capability in Liberia, Africa to support a clinical trial of convalescent plasma therapy for Ebola Virus Disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A bloodmobile was outfitted in the United States as a four\u2010bed apheresis unit with capabilities including pathogen reduction, electronic blood establishment computer system, designated areas for donor counseling and laboratory testing, and onboard electrical power generation. After air transport to Liberia, the bloodmobile was positioned at ELWA Hospital, Monrovia, and connected to the hospital's power grid. Liberian staff were trained to conduct donor screening, which included questionnaire and onsite blood typing and transfusion transmitted infection (TTI) testing, and plasma collection and processing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The bloodmobile was operational within 3 weeks after arrival of the advance team. Of 101 donors who passed the pre\u2010screening questionnaire, 32 were deferred. Twenty\u2010eight of ninty\u2010nine tested survivors were deferred for positive transfusion transmitted infection (TTI) tests; twenty\u2010one were positive for hepatitis B, hepatitis C, or human immunodeficiency virus. The majority of donors had type O blood; all but one were Rh positive. Forty\u2010three survivors donated at least once; eighty\u2010nine apheresis attempts resulted in eighty\u2010one successful collections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Apheresis capability was emergently established in Liberia to support an efficacy trial of Ebola Convalescent Plasma. Extensive cooperation among multinational team members, engineers, logisticians, and blood safety technical personnel at the operational site was required to surmount challenges to execution posed by logistical factors. The high proportion of positive TTI tests supported the use of a pathogen reduction system to enhance product safety. J. Clin. Apheresis 32:175\u2013181, 2017. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jca.21482","type":"journal-article","created":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T04:56:47Z","timestamp":1468040207000},"page":"175-181","source":"Crossref","is-referenced-by-count":16,"title":["Apheresis for collection of Ebola convalescent plasma in Liberia"],"prefix":"10.1002","volume":"32","author":[{"given":"Jerry F.","family":"Brown","sequence":"first","affiliation":[{"name":"Eternal Love Winning Africa Hospital Paynesville Liberia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Rowe","sequence":"additional","affiliation":[{"name":"Blood Centers of America West Warwick RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zacharias","sequence":"additional","affiliation":[{"name":"Safe Blood for Africa Foundation Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"van Hasselt","sequence":"additional","affiliation":[{"name":"Safe Blood for Africa Foundation Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Dye","sequence":"additional","affiliation":[{"name":"Division of Virology United States Army Medical Research Institute of Infectious Disease Frederick MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Wohl","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine Chapel Hill NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"2nd","given":"William A.","family":"Fischer","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine Chapel Hill NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleen K.","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan M.","family":"Thielman","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Hoover","sequence":"additional","affiliation":[{"name":"Clinical Research Management, Inc  OH Hinckley"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,8]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Centers for Disease Control and Prevention.Outbreaks Chronology: Ebola Virus Disease.2016.http:\/\/www.cdc.gov\/vhf\/ebola\/outbreaks\/history\/chronology.html. [cited 2016 2\/22\/16]."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1413084"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201408-1514CP"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00144-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ319"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.12.005"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.141061"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/514298"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200409109"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504874"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000191"},{"key":"e_1_2_7_13_1","unstructured":"Blood Regulators Network WHO.Position Paper on Collection and Use of Convalescent Plasma or Serum as an Element in Filovirus Outbreak Response 2014."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ680"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511812"},{"key":"e_1_2_7_16_1","unstructured":"Center for Biologics Evaluation and Research FDA.Guidance for Industry: Implementation of an Acceptable Abbreviated Donor History Questionnaire and Accompanying Materials for Use in Screening Frequent Donors of Blood and Blood Components.2013 FDA CBER: Maryland."},{"key":"e_1_2_7_17_1","unstructured":"AABB. Circular of Information for the Use of Human Blood and Blood Components.2013 AABB: Bethesda MD."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500306"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.12.011"},{"key":"e_1_2_7_20_1","first-page":"613","article-title":"Progress toward prevention of transfusion\u2010transmitted hepatitis B and hepatitis C infection\u2013sub\u2010Saharan Africa, 2000\u20102011","volume":"63","author":"Apata IW","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"e_1_2_7_21_1","unstructured":"UN Aids. HIV and Aids Estimates LIberia.2014.http:\/\/www.unaids.org\/en\/regionscountries\/countries\/liberia[cited 2016 2\/9\/16]."}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21482","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21482","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:57:20Z","timestamp":1695574640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,8]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/jca.21482"],"URL":"https:\/\/doi.org\/10.1002\/jca.21482","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,8]]}}}